Benitec Biopharma
BNTC
3 hedge funds and large institutions have $414K invested in Benitec Biopharma in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.06% less ownership
Funds ownership: 3.38% → 3.31% (-0.06%)
23% less capital inflows, than outflows
Capital inflows: $24K | Capital outflows: $31.1K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$30.1K |
| 2 |
Tower Research Capital (TRC)
New York
|
-$1K |
BNTC Hedge Fund Activity: Q4 2016 in Review
3 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2016, worth a combined $414K — up 7.3% from $386K a quarter earlier.
Fund positioning in BNTC was balanced in Q4 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $24K. The largest seller was Sabby Management, cutting an estimated $30.1K.
- 3 institutional investors held Benitec Biopharma (BNTC) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $414K of Benitec Biopharma stock for Q4 2016, up 7.3% quarter-over-quarter.
- 1 fund opened new Benitec Biopharma positions in Q4 2016 and 1 closed out, a net change of 0 holders.
- The largest Benitec Biopharma buyer in Q4 2016 was Citadel Advisors, an estimated $24K added.
- The largest Benitec Biopharma seller in Q4 2016 was Sabby Management, an estimated $30.1K sold.
Based on aggregated 13F filings for Q4 2016.